High Quality Ceftriaxone Injection, Bronchial Asthma, Imiquimod Cream Suppliers in China

Home > Products > Antibiotics > Difen-Guyenne B12 Diclofenac Potassiumbetamethasone Sodium

Difen-Guyenne B12 Diclofenac Potassiumbetamethasone Sodium

Basic Info

Model No.:  OV-16051804

Product Description

Model NO.: OV-16051804 Usage Mode: For external use State: Liquid Type: Organic Chemicals Drug Reg./Approval No.: 1 Color: as Your Requirement Specification: 10vial+10amp/tray, 2tray/box HS Code: 3001909010 Application: Surgery Suitable for: Elderly, Adult Shape: Oral Liquid Pharmaceutical Technology: Chemical Synthesis Drug Ad Approval No.: 1 Trademark: OEM Origin: China DIFEN-GUYENNE B12 DICLOFENAC POTASSIUMBETAMETHASONE SODIUM
Diclofenac Potassium - Clinical Pharmacology
Pharmacodynamics
Diclofenac Potassium is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Diclofenac Potassium, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
Pharmacokinetics
Absorption
Diclofenac is 100% absorbed after oral administration compared to IV administration as measured by urine recovery. However, due to first-pass metabolism, only about 50% of the absorbed dose is systemically available (see Table 1). In some fasting volunteers, measurable plasma levels are observed within 10 minutes of dosing with Diclofenac Potassium. Peak plasma levels are achieved approximately one hour in fasting normal volunteers, with a range of .33 to 2 hours. Food has no significant effect on the extent of diclofenac absorption. However, there is usually a delay in the onset of absorption and a reduction in peak plasma levels of approximately 30%.
Special Populations

Pediatric
The pharmacokinetics of Diclofenac Potassium has not been investigated in pediatric patients.
Race
Pharmacokinetic differences due to race have not been identified.
Hepatic Insufficiency
Hepatic metabolism accounts for almost 100% of Diclofenac Potassium elimination, so patients with hepatic disease may require reduced doses of Diclofenac Potassium compared to patients with normal hepatic function.
Renal Insufficiency

Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60 to 90, 30 to 60, and < 30 mL/min; N = 6 in each group), AUC values and elimination rate were comparable to those in healthy subjects.
 

Contact us if you need more details on Diclofenac Potassium. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Nsaid、Gynaecology. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Antibiotics

Email to this supplier
  • *Subject:
  • To:

  • *Messages:
    Your message must be between 20-8000 characters